Form 8K Lantern Pharma Inc For: 23 January
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Lantern Pharma Inc (LTRN)
Lantern Pharma Inc stock price live, this page displays NASDAQ LTRN stock exchange data. View the LTRN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Lantern Pharma Inc real time stock price chart below.
What Is the Lantern Pharma Inc Stock Price Today?
The Lantern Pharma Inc stock price today is 3.46.
What Is the Stock Symbol for Lantern Pharma Inc?
The stock symbol for Lantern Pharma Inc is "LTRN."
What Stock Exchange Does Lantern Pharma Inc Trade On?
Lantern Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is Lantern Pharma Inc a Good Stock to Buy?
Determining whether Lantern Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LTRN quote. (ISIN: US51654W1018)
What Is the Lantern Pharma Inc Stock Price Today?
The Lantern Pharma Inc stock price today is 3.46.
What Is the Stock Symbol for Lantern Pharma Inc?
The stock symbol for Lantern Pharma Inc is "LTRN."
What Stock Exchange Does Lantern Pharma Inc Trade On?
Lantern Pharma Inc is listed and trades on the NASDAQ stock exchange.
Is Lantern Pharma Inc a Good Stock to Buy?
Determining whether Lantern Pharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the LTRN quote. (ISIN: US51654W1018)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.41
3.59
52 wk Range
2.55
5.74
LTRN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.413.59
52 wk Range
2.555.74
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
LTRN Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
22.00
Upside
+535.84%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Neutral
Moving Averages
Buy
Lantern Pharma Inc Company Profile
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin’s lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Lantern Pharma Inc Earnings Call Summary for Q3/2025
- Lantern Pharma reported Q3 2025 net loss of $4.2M ($0.39/share), improving from $4.5M loss in Q3 2024, with stock rising 6.32% to $3.61 in pre-market trading
- R&D expenses decreased to $2.4M from $3.7M year-over-year, while the company maintains a $12.4M cash position expected to fund operations into Q3 2026
- Strategic initiatives include transitioning CRO services and expanding operations in Japan, positioning Lantern as a leader in AI-driven precision oncology
- Near-term catalysts include a KOL webinar for LP-184 in November, LP-300 interim data in December, and IND application for pediatric CNS program in early 2026
- CEO Panna Sharma emphasized 'fundamentally reimagining what's possible in precision oncology' through the company's innovative AI-driven approach
Last Updated: 2025-11-13, 10:26 a/m
Read Full TranscriptCompare LTRN to Peers and Sector
Metrics to compare | LTRN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipLTRNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.0x | −4.4x | −0.6x | |
PEG Ratio | −1.73 | −0.13 | 0.00 | |
Price/Book | 4.0x | 5.8x | 2.6x | |
Price / LTM Sales | - | 11.2x | 3.4x | |
Upside (Analyst Target) | - | 50.7% | 42.0% | |
Fair Value Upside | Unlock | −1.8% | 5.0% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 22.00
(+535.84% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.39 / -0.44
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Lantern Pharma (LTRN) Stock Price Today?
The Lantern Pharma stock price today is 3.46
What Stock Exchange Does Lantern Pharma Trade On?
Lantern Pharma is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Lantern Pharma?
The stock symbol for Lantern Pharma is "LTRN."
What Is the Lantern Pharma Market Cap?
As of today, Lantern Pharma market cap is 38.70M.
What Is Lantern Pharma's Earnings Per Share (TTM)?
The Lantern Pharma EPS (TTM) is -1.75.
When Is the Next Lantern Pharma Earnings Date?
Lantern Pharma will release its next earnings report on Mar 05, 2026.
From a Technical Analysis Perspective, Is LTRN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Lantern Pharma Stock Split?
Lantern Pharma has split 0 times.
How Many Employees Does Lantern Pharma Have?
Lantern Pharma has 24 employees.
What is the current trading status of Lantern Pharma (LTRN)?
As of Jan 24, 2026, Lantern Pharma (LTRN) is trading at a price of 3.46, with a previous close of 3.53. The stock has fluctuated within a day range of 3.41 to 3.59, while its 52-week range spans from 2.55 to 5.74.
What Is Lantern Pharma (LTRN) Price Target According to Analysts?
The average 12-month price target for Lantern Pharma is USD22.00, with a high estimate of USD26 and a low estimate of USD15. 2 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +535.84% Upside potential.
What Is the LTRN After Hours Price?
LTRN's last after hours stock price is 3.44, the stock has decreased by -0.02, or -0.58%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.